ReviewCurrent allergy and asthma reports2026
Targeting Type 2 and Non-type 2 Asthma: Emerging Biologics and Personalized Strategies.
Review in Current allergy and asthma reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAsthma continues to pose a serious global health issue affecting billions of people and causing significant morbidity. It is immunologically heterogeneous disease, classified as Type 2 (Th2/ILC2-mediated, eosinophilic) or Type 1 (Th1-mediated, neutrophilic, steroid-resistant) inflammation. This review aims to evaluates current biologic therapies, emerging strategies, and challenges in asthma management and highlights the challenges and future directions in personalized asthma management. RECENT
findingsCurrent biologics for Type 2 asthma like anti-IgE (omalizumab), anti-IL-5 (mepolizumab, reslizumab, benralizumab), anti-IL-4/IL-13 (dupilumab) and anti-TSLP (tezepelumab) were effectively controlling severe eosinophilic asthma. Emerging therapies for Type 1 and mixed phenotypes include anti-TNF-α agents, CXCR2 antagonists, IL-17 blockers, JAK-STAT inhibitors and microbiome-based approaches and upstream epithelial cytokine-targeting therapies such as anti-TSLP agents. Dual or broad-spectrum strategies, such as bispecific antibodies and endotype-guided biologic selection offer more targeted interventions. Despite these advances, challenges persist regarding high costs, limited accessibility, absence of robust biomarkers, and potential risks of immunosuppression. Biologics have transformed severe Type 2 asthma management, but effective treatments for Type 1 and steroid-resistant asthma remain limited. Future directions involve multi-omics, machine learning and gene therapy to optimize personalized therapy and develop inclusive strategies for the diverse inflammatory endotypes.
Indexed as
Identifiers
42223828What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.